LONDON, Ontario, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Sernova Corp (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be participating at the 10th annual Biotech Showcase Conference in San Francisco, CA. Sernova’s focus will be on meeting with potential partners for its developing technologies.
“We see this gathering of international pharmaceutical executives as an excellent opportunity to have new and ongoing discussions with potential industry partners, especially given the recent clearance by FDA to initiate Sernova’s US clinical study of our novel implantable Cell Pouch device with therapeutic cells as a next step regenerative medicine treatment for diabetes. We will be discussing Sernova’s regenerative medicine platform including our clinical trial for patients with type 1 diabetes and our product development advancements,” remarked Dr. Philip Toleikis, President and CEO.
About Biotech Showcase(TM)
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
About Sernova
Sernova Corp is a clinical stage regenerative medicine Company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including hemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch, an implantable medical device and therapeutic cells (donor, xenogeneic or stem cell derived therapeutic cells) which then release proteins and/or hormones as required. Sernova’s Cell Pouch and therapeutic cell technologies have shown therapeutic cell survival and efficacy in a vascularized tissue environment without the issue of fibrosis, a particular problem for many implantable medical devices.
For further information contact:
Philip Toleikis, Ph.D., President and CEO
Tel: (604) 961-2939
philip.toleikis@sernova.com
info@sernova.com
www.sernova.com
Ray Matthews & Associates
Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6
Tel: (604) 818-7778
www.raymatthews.ca
Forward Looking Information
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements, which include our beliefs about the functionality of the Cell Pouch and our cell technologies, are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.